VLA.PA stock down 39.01% to €2.78 pre-market: Pfizer trial shifts valuation outlook

VLA.PA stock plunged 39.01% to €2.78 in pre-market trading on 24 Mar 2026 after a spike in volume and fresh Pfizer-Valneva Lyme vaccine headlines. The move followed heavy selling: 9,307,863 shares traded versus an average of 1,124,682. Traders priced in faster regulatory action and profit-taking despite positive Phase 3 efficacy data, leaving the EURONEXT-listed Valneva SE in focus for Europe healthcare investors.